[53]], targeting the JAK/STAT pathway using Baracitinib – approved for moderate to severe arthritis [54] – recently shown to reduce time-to-recovery for hospitalized COVID-19 patients in combination with Remdesivir [55], however, caution is warranted [56]. This evidence concerns the gene SOAT1 and arthritic joint disease.